½ÃÀ庸°í¼­
»óǰÄÚµå
1404711

Á¤¸ÆÁÖ»ç¾× ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : Á¦Ç°º°, ¿µ¾ç¼Òº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2030³â)

Intravenous Solutions Market Size, Share & Trends Analysis Report By Product (TPN, PPN), By Nutrients (Carbohydrates, Vitamins & Minerals, Single-dose Amino Acids) By Region (Asia Pacific, North America), And Segment Forecasts, 2024 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 114 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Á¤¸ÆÁÖ»ç¾× ½ÃÀå ¼ºÀå ¹× µ¿Çâ:

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é, ¼¼°è Á¤¸ÆÁÖ»ç¾× ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 220¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È 8%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ƯÈ÷ Àεµ, Áß±¹ µî ½ÅÈï±¹¿¡¼­´Â Á¶»êÀ²ÀÌ ³ô¾Æ ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÉ °ÍÀ¸·Î ¿¹»óµÇ¸ç, WHO¿¡ µû¸£¸é 10 ¸í Áß 1 ¸íÀº Á¶»ê¾Æ·Î Àü ¼¼°è°¡ ¿ì·ÁÇϰí ÀÖ´Â »óȲÀÔ´Ï´Ù. µû¶ó¼­ ½ÅÈï±¹ÀÇ ³ôÀº Á¶»ê ¹ß»ý·ü, ÀÇ·á ÀÎÇÁ¶ó °³¼±, ÀÇ·áºñ ¹× ȯÀÚ ÀÎ½Ä Áõ°¡´Â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ÃËÁø¿äÀÎÀ¸·Î Å« ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºñ°æ±¸ ÁöÁú ¿¡¸ÖÀüÀÇ »ç¿ëÀº Á¶»êÀ¸·Î ÀÎÇÑ »ç¸Á·üÀ» ³·Ãß±â À§ÇØ ¿©·¯ ´ç±¹ÀÌ ±¤¹üÀ§ÇÏ°Ô ÃÊÁ¡À» ¸ÂÃß°í ÀÖÀ¸¸ç, 2021³â ÇöÀç ¹Ì±¹ÀÇ Á¶»êÀ²Àº ¾à 10.5%¿¡ ´ÞÇÕ´Ï´Ù. ¶ÇÇÑ Á¶»êÀ¸·Î ÀÎÇÑ »çȸÀû, °æÁ¦Àû ºñ¿ëÀº ¿¬°£ 252¾ï ´Þ·¯¿¡ ´ÞÇÏ´Â °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. µû¶ó¼­, Ãâ»ê ÈÄ º¸Á¶ ¿µ¾çÀ» ÇÊ¿ä·Î ÇÏ´Â ½Å»ý¾ÆµéÀÌ ¸¹´Ù´Â Á¡Àº ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ö¿ä¸¦ Áõ°¡½Ãų °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¶ÇÇÑ, ÆÒµ¥¹Í ±â°£ µ¿¾È Áõ°¡µÈ ¿µ¾ç½ÇÁ¶ ¹®Á¦·Î °íÅë¹Þ´Â ȯÀڵ鿡°Ô ºñ°æ±¸ ¿µ¾çÁ¦ »ç¿ëÀ» Á¤´çÈ­ÇÏ´Â ¿©·¯ ¿¬±¸µµ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, Journal of the Academy of Nutrition and Dietetics¿¡ °ÔÀçµÈ ³í¹®¿¡ µû¸£¸é, COVID-19 Ä¡·á¸¦ À§ÇØ ÁßȯÀڽǿ¡ ÀÔ¿øÇÑ È¯ÀÚ Áß »ó´ç¼ö°¡ ±Þ¼º ¿µ¾ç½ÇÁ¶·Î °íÅë¹Þ°í ÀÖ½À´Ï´Ù. µû¶ó¼­ ÆÒµ¥¹Í ±â°£ µ¿¾È ½ÃÀå¿¡¼­ ºñ°æ±¸ ¿µ¾ç Á¦Ç°ÀÇ »ç¿ë·®ÀÌ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

COVID-19 ¾ç¼º ȯÀÚ¿¡¼­ ƯÁ¤ ¹Ì·® ¿µ¾ç¼Ò¿Í ºñŸ¹ÎÀÌ °áÇÌµÈ °æ¿ì°¡ ¸¹¾Æ À¯ÇØÇÑ °ÍÀ¸·Î º¸°íµÇ°í ÀÖ½À´Ï´Ù. µû¶ó¼­ ÀÌ·¯ÇÑ È¯ÀÚµéÀº ±ÇÀå ½ÄÀÌ ¼·Ãë·®À» ÃæÁ·½Ã۱â À§ÇØ Á¤¸ÆÁֻ縦 ±ÇÀåÇϰí ÀÖ½À´Ï´Ù. ÀÇ»ç¿Í ¿µ¾ç Àü¹®°¡µéÀº COVID-19 ȯÀÚ¿¡¼­ °æÀ念¾çº¸´Ù ºñ°æ±¸¿µ¾çÀ» ¼±È£Çß½À´Ï´Ù. ƯÈ÷ °æÀ念¾çÀº ºñÀ§°ü ¼³Ä¡°¡ ÇÊ¿äÇØ COVID-19 ȯÀÚ¿¡°Ô Á¦°øµÇ´Â ºñħ½ÀÀû ÀΰøÈ£ÈíÀ» ¹æÇØÇϱ⠶§¹®¿¡ COVID-19 ÀÔ¿ø ȯÀÚ¿¡¼­ ¿µ¾ç ¿ë¾× ÈíÀÎ ¹× ¿µ¾ç ºÎÁ·ÀÇ À§ÇèÀÌ ³ô¾ÆÁ® ºñ°æ±¸¿µ¾ç äÅÃÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

Á¤¸ÆÁÖ»ç¾× ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • 2023³â¿¡´Â Á¾ÇÕºñ°æ±¸¿µ¾ç(TPN) ºÐ¾ß°¡ 66.3%·Î ¾ÐµµÀûÀÎ ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÏ¸ç ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº ¼ºÀå·ü(CAGR 8.2%)À» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµÇ¸ç, TPNÀº Á¤¸Æ ³»(IV) ±â¼úÀ» ÅëÇØ Á¾ÇÕÀûÀÎ ¿µ¾ç ¼¼Æ®¸¦ Åõ¿©ÇÏ´Â °ÍÀ» Æ÷ÇÔÇÕ´Ï´Ù.
  • 2023³â¿¡´Â 1ȸ¿ë ¾Æ¹Ì³ë»ê ¿ë¾× ºÎ¹®ÀÌ ½ÃÀåÀ» ÁÖµµÇϸç 31.6%ÀÇ Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ¿¬±¸¿¡ µû¸£¸é ´ÜÀÏ ¿ë·® ¾Æ¹Ì³ë»êÀº ¿ÏÀüÇÑ ´Ü¹éÁú °ø±Þ¿øÀ» Á¦°øÇÏ°í ´Ù¸¥ ºñ°æ±¸ Á¦Á¦¿Í ÇÔ²² ½±°Ô ¸ÂÃãÈ­ ÇÒ ¼ö ÀÖÀ¸¸ç Åõ¿©°¡ ¿ëÀÌÇÕ´Ï´Ù.
  • Assure Infusions, Inc.°¡ ¹Ì±¹ ³» ¼ö¾× °ø±Þ°ú ¼ö¿äÀÇ °ÝÂ÷¸¦ ÇØ¼ÒÇϱâ À§ÇØ ¹Ì±¹ Ç÷θ®´Ù ÁÖ Bartow¿¡ ÷´Ü Á¦Á¶ ½Ã¼³À» °Ç¼³Çϱâ À§ÇØ 2,000¸¸ ´Þ·¯¸¦ ÅõÀÚÇÒ °ÍÀ̶ó°í ¹ßÇ¥Çß½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¤¸ÆÁÖ»ç¾× ½ÃÀå º¯¼ö¿Í µ¿Çâ

  • Á¤¸ÆÁÖ»ç¾× ½ÃÀå °èÅë Àü¸Á
    • ºÎ¼ö ½ÃÀå Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎÀÇ ¿µÇ⠺м®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • ±ÔÁ¦ ü°è
    • ±Ô°Ý°ú ÁذÅ
    • »óȯ ½Ã³ª¸®¿À
  • COVID-19 ÆÒµ¥¹ÍÀÇ ¿µÇâ
  • ¾÷°è ºÐ¼® Åø
    • Porters ºÐ¼®
    • °Å½Ã°æÁ¦ ºÐ¼®

Á¦4Àå Á¤¸ÆÁÖ»ç¾× ½ÃÀå : Á¦Ç° ºÐ¼®

  • Á¦Ç° º¯µ¿ ºÐ¼®°ú ½ÃÀå Á¡À¯À², 2023³â°ú 2030³â
  • Á¦Ç°º°
  • ¿ÏÀü Á¤¸Æ ¿µ¾ç
    • ¿ÏÀü Á¤¸Æ ¿µ¾ç ½ÃÀå, 2018-2030³â
  • ¸»ÃÊ Á¤¸Æ ¿µ¾ç
    • ¸»ÃÊ Á¤¸Æ ¿µ¾ç ½ÃÀå, 2018-2030³â

Á¦5Àå Á¤¸ÆÁÖ»ç¾× ½ÃÀå : ¿µ¾ç¼Ò ºÐ¼®

  • ¿µ¾ç¼Ò º¯µ¿ ºÐ¼®°ú ½ÃÀå Á¡À¯À², 2023³â°ú 2030³â
  • ¿µ¾ç¼Òº°
  • ź¼öÈ­¹°
    • ź¼öÈ­¹° ½ÃÀå, 2018-2030³â
  • ÀÏȸ Åõ¿© ¾Æ¹Ì³ë»ê ¿ë¾×
    • ÀÏȸ Åõ¿© ¾Æ¹Ì³ë»ê ¿ë¾× ½ÃÀå, 2018-2030³â
  • ºñŸ¹Î°ú ¹Ì³×¶ö
    • ºñŸ¹Î°ú ¹Ì³×¶ö, 2018-2030³â
  • ºñ°æ±¸ ÁöÁú ¿¡¸ÖÀü
    • ºñ°æ±¸ ÁöÁú ¿¡¸ÖÀü, 2018-2030³â
  • ±âŸ
    • ±âŸ ½ÃÀå, 2018-2030³â

Á¦6Àå Á¤¸ÆÁÖ»ç¾× ½ÃÀå : Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®

  • Á¤¸ÆÁÖ»ç¾× ½ÃÀå : Áö¿ªº° Àü¸Á
  • ºÏ¹Ì
    • ºÏ¹ÌÀÇ Á¤¸ÆÁÖ»ç¾× ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • À¯·´ÀÇ Á¤¸ÆÁÖ»ç¾× ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • µ§¸¶Å©
    • ½º¿þµ§
    • ³ë¸£¿þÀÌ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Á¤¸ÆÁÖ»ç¾× ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ű¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ Á¤¸ÆÁÖ»ç¾× ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
    • ¸ß½ÃÄÚ
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«(MEA)
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Á¤¸ÆÁÖ»ç¾× ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • Äí¿þÀÌÆ®

Á¦7Àå °æÀï ºÐ¼®

  • ±â¾÷ ºÐ·ù
    • Fresenius Kabi AG
    • Pfizer Inc.
    • Otsuka Pharmaceutical Co. Ltd.
    • Baxter, B. Braun Melsungen AG
    • Vifor Pharma Management Ltd.
    • JW Life Science
  • Âü¿©ÀÚ °³¿ä
  • À繫 ½ÇÀû
  • Á¦Ç° º¥Ä¡¸¶Å©
  • ½ÃÀå ÁøÃâ ±â¾÷ ºÐ·ù
    • È÷Æ®¸Ê ºÐ¼®
  • ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®, 2022³â
  • Àü·« ¸ÅÇÎ
    • ÀμöÇÕº´
    • Á¦Ç° ¹ß¸Å
    • ÆÄÆ®³Ê½Ê°ú Çù¾÷
    • Á¦Ç° ½ÂÀÎ
    • È®´ë
    • ±âŸ

Á¦8Àå ¾Ö³Î¸®½ºÆ®ÀÇ °ßÇØ

ksm 24.01.17

Intravenous Solutions Market Growth & Trends:

The global intravenous solutions market size is expected to reach USD 22.0 billion by 2030, registering a CAGR of 8% during the forecast period, according to a new report by Grand View Research, Inc. The high prevalence of preterm births, especially in emerging economies such as India and China, is expected to drive market growth during the forecast period. According to WHO, 1 in 10 babies are born preterm, and this is a global concern. Thus, the high incidence of preterm births in emerging economies, improved healthcare infrastructure, and growing healthcare expenditure & patient awareness are expected to be high impact rendering drivers of the market during the forecast period.

The use of parenteral lipid emulsions is driven by the extensive focus of various authorities to limit preterm birth mortality. As of 2021, the preterm birth rate in the U.S. was about 10.5%. Moreover, the annual societal, and economic cost was estimated at USD 25.2 billion for preterm births. Hence, the presence of many neonates requiring supplementary postbirth nutrition is expected to boost the market demand over the forecast period.

In addition, several studies justify the use of parenteral nutrition for patients suffering from malnutrition problems, which increased during the pandemic, leading to market growth. For instance, according to an article published in the Journal of the Academy of Nutrition and Dietetics, many patients admitted to the ICU for COVID-19 treatment suffer from acute malnourishment. Hence, the usage of parenteral nutrition products is expected to increase in the market during the pandemic.

In COVID-19-positive patients, high deficiency of specific micronutrients and vitamins has been reported to be detrimental. Thus, intravenous administration is recommended in such patients to meet the recommended dietary intake. Physicians and nutrition specialists preferred parenteral nutrition over enteral nutrition in COVID-19 patients since enteral nutrition specifically requires the setup of nasogastric tubes, which hampers the noninvasive ventilation provided to COVID-19 patients. The increased risk of nutritional solution aspiration and underfeeding in hospitalized patients for COVID-19 has led to increased adoption of parenteral nutrition.

Intravenous Solutions Market Report Highlights:

  • In 2023, the Total Parenteral Nutrition (TPN) segment held a dominant market share of 66.3% and is projected to experience the highest growth rate (CAGR of 8.2%) during the forecast period. TPN involves administering a comprehensive set of nutrients through an intravenous (IV) technique
  • In 2023, the market was led by the single-dose amino acid solution segment, holding a significant share of 31.6%. Studies have shown that single-dose amino acids offer a complete protein source, are easily customizable with other parenteral formulations, and are straightforward to administer
  • In 2023, North America held a dominant market share of 41%, credited to key players, favorable regulations, and strong reimbursement in countries like the U.S. Assure Infusions, Inc. announced a USD 20 million investment to build an advanced manufacturing facility in Bartow, Florida, addressing the IV solutions demand-supply gap in the U.S.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation
    • 1.1.1 Segment Definitions
      • 1.1.1.1 Product Segment
      • 1.1.1.2 Nutrient Segment
  • 1.2 Regional Scope
  • 1.3 Estimates And Forecast Timeline
  • 1.4 Objectives
    • 1.4.1 Objective - 1
    • 1.4.2 Objective - 2
    • 1.4.3 Objective - 3
  • 1.5 Research Methodology
  • 1.6 Information Procurement
    • 1.6.1 Purchased Database
    • 1.6.2 GVR's Internal Database
    • 1.6.3 Secondary Sources
    • 1.6.4 Primary Research
  • 1.7 Information Or Data Analysis
    • 1.7.1 Data Analysis Models
  • 1.8 Market Formulation & Validation
  • 1.9 Model Details
    • 1.9.1 Commodity Flow Analysis
      • 1.9.1.1 Research Scope And Assumptions
  • 1.10 List Of Secondary Sources
  • 1.11 List Of Primary Sources
  • 1.12 List Of Abbreviations

Chapter 2 Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Segment Snapshot
  • 2.3 Competitive Landscape

Chapter 3 Intravenous Solutions Market Variables And Trends

  • 3.1 Intravenous Solutions Market Lineage Outlook
    • 3.1.1 Ancillary Market Outlook
  • 3.2 Market Dynamics
    • 3.2.1 Market Driver Impact Analysis
      • 3.2.1.1 Growing Number Of Premature Births
      • 3.2.1.2 Increasing Incidence Of Cancer
      • 3.2.1.3 Increasing Risk Of Malnutrition
      • 3.2.1.4 Growing Geriatric Population
    • 3.2.2 Market Restraint Analysis
      • 3.2.2.1 Shortage Of Parenteral Nutrition Products
      • 3.2.2.2 Increased Use Of Enteral Nutrition
      • 3.2.2.3 High Risk Of Infections
  • 3.3 Regulatory Framework
    • 3.3.1 Standards And Compliances
      • 3.3.1.1 North America
      • 3.3.1.2 Europe
      • 3.3.1.3 Apac
      • 3.3.1.4 Latin America
      • 3.3.1.5 Mea
    • 3.3.2 Reimbursement Scenario
      • 3.3.2.1 U.S.
      • 3.3.2.2 Canada
      • 3.3.2.3 Germany
      • 3.3.2.4 UK
      • 3.3.2.5 Japan
      • 3.3.2.6 Australia
      • 3.3.2.7 China
  • 3.4 Impact Of Covid-19 Pandemic
  • 3.5 Industry Analysis Tools
    • 3.5.1 Porter's Analysis
    • 3.5.2 Macroeconomic Analysis

Chapter 4 Intravenous Solutions Market: Product Analysis

  • 4.1 Product Movement Analysis & Market Share, 2023 & 2030
  • 4.2 Intravenous Solutions Market Estimates & Forecast, By Product (Revenue In USD Million And Volume In Thousand Units)
  • 4.3 Total Parenteral Nutrition
    • 4.3.1 Total Parenteral Nutrition Market, 2018 - 2030 (Revenue In USD Million And Volume In Thousand Units)
  • 4.4 Peripheral Parenteral Nutrition
    • 4.4.1 Peripheral Parenteral Nutrition Market, 2018 - 2030 (Revenue In USD Million And Volume In Thousand Units)

Chapter 5 Intravenous Solutions Market: Nutrients Analysis

  • 5.1 Nutrients Movement Analysis & Market Share, 2023 & 2030
  • 5.2 Intravenous Solutions Market Estimates & Forecast, By Nutrients (Revenue In USD Million And Volume In Thousand Units)
  • 5.3 Carbohydrates
    • 5.3.1 Carbohydrates Market, 2018 - 2030 (Revenue In USD Million And Volume In Thousand Units)
  • 5.4 Single-dose Amino Acid Solution
    • 5.4.1 Single-dose Amino Acid Solution Market, 2018 - 2030 (Revenue In USD Million And Volume In Thousand Units)
  • 5.5 Vitamins & Minerals
    • 5.5.1 Vitamins & Minerals, 2018 - 2030 (Revenue In USD Million And Volume In Thousand Units)
  • 5.6 Parenteral Lipid Emulsion
    • 5.6.1 Parenteral Lipid Emulsion, 2018 - 2030 (Revenue In USD Million And Volume In Thousand Units)
  • 5.7 Others
    • 5.7.1 Others Market, 2018 - 2030 (Revenue In USD Million And Volume In Thousand Units)

Chapter 6 Intravenous Solutions Market: Regional Estimates & Trend Analysis

  • 6.1 Intravenous Solutions Market: Regional Outlook
  • 6.2 North America
    • 6.2.1 North America Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (Revenue In USD Million And Volume In Thousand Units)
    • 6.2.2 U.S.
      • 6.2.2.1 Key Country Dynamics
      • 6.2.2.2 U.S. Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (Revenue In USD Million And Volume In Thousand Units)
    • 6.2.3 Canada
      • 6.2.3.1 Key Country Dynamics
      • 6.2.3.2 Canada Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (Revenue In USD Million And Volume In Thousand Units)
  • 6.3 Europe
    • 6.3.1 Europe Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (Revenue In USD Million And Volume In Thousand Units)
    • 6.3.2 UK
      • 6.3.2.1 Key Country Dynamics
      • 6.3.2.2 UK Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (Revenue In USD Million And Volume In Thousand Units)
    • 6.3.3 Germany
      • 6.3.3.1 Key Country Dynamics
      • 6.3.3.2 Germany Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (Revenue In USD Million And Volume In Thousand Units)
    • 6.3.4 France
      • 6.3.4.1 Key Country Dynamics
      • 6.3.4.2 France Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (Revenue In USD Million And Volume In Thousand Units)
    • 6.3.5 Italy
      • 6.3.5.1 Key Country Dynamics
      • 6.3.5.2 Italy Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (Revenue In USD Million And Volume In Thousand Units)
    • 6.3.6 Spain
      • 6.3.6.1 Key Country Dynamics
      • 6.3.6.2 Spain Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (Revenue In USD Million And Volume In Thousand Units)
    • 6.3.7 Denmark
      • 6.3.7.1 Key Country Dynamics
      • 6.3.7.2 Denmark Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (Revenue In USD Million And Volume In Thousand Units)
    • 6.3.8 Sweden
      • 6.3.8.1 Key Country Dynamics
      • 6.3.8.2 Sweden Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (Revenue In USD Million And Volume In Thousand Units)
    • 6.3.9 Norway
      • 6.3.9.1 Key Country Dynamics
      • 6.3.9.2 Norway Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (Revenue In USD Million And Volume In Thousand Units)
  • 6.4 Asia Pacific
    • 6.4.1 Asia Pacific Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (Revenue In USD Million And Volume In Thousand Units)
    • 6.4.2 Japan
      • 6.4.2.1 Key Country Dynamics
      • 6.4.2.2 Japan Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (Revenue In USD Million And Volume In Thousand Units)
    • 6.4.3 China
      • 6.4.3.1 Key Country Dynamics
      • 6.4.3.2 China Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (Revenue In USD Million And Volume In Thousand Units)
    • 6.4.4 India
      • 6.4.4.1 Key Country Dynamics
      • 6.4.4.2 India Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (Revenue In USD Million And Volume In Thousand Units)
    • 6.4.5 Australia
      • 6.4.5.1 Key Country Dynamics
      • 6.4.5.2 Australia Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (Revenue In USD Million And Volume In Thousand Units)
    • 6.4.6 South Korea
      • 6.4.6.1 Key Country Dynamics
      • 6.4.6.2 South Korea Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (Revenue In USD Million And Volume In Thousand Units)
    • 6.4.7 Thailand
      • 6.4.7.1 Key Country Dynamics
      • 6.4.7.2 Thailand Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (Revenue In USD Million And Volume In Thousand Units)
  • 6.5 Latin America
    • 6.5.1 Latin America Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (Revenue In USD Million And Volume In Thousand Units)
    • 6.5.2 Mexico
      • 6.5.2.1 Key Country Dynamics
      • 6.5.2.2 Mexico Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (Revenue In USD Million And Volume In Thousand Units)
    • 6.5.3 Brazil
      • 6.5.3.1 Key Country Dynamics
      • 6.5.3.2 Brazil Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (Revenue In USD Million And Volume In Thousand Units)
    • 6.5.4 Argentina
      • 6.5.4.1 Key Country Dynamics
      • 6.5.4.2 Argentina Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (Revenue In USD Million And Volume In Thousand Units)
  • 6.6 Middle East & Africa (Mea)
    • 6.6.1 Mea Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (Revenue In USD Million And Volume In Thousand Units)
    • 6.6.3 South Africa
      • 6.6.3.1 Key Country Dynamics
      • 6.6.3.2 South Africa Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (Revenue In USD Million And Volume In Thousand Units)
    • 6.6.4 Saudi Arabia
      • 6.6.4.1 Key Country Dynamics
      • 6.6.4.2 Saudi Arabia Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (Revenue In USD Million And Volume In Thousand Units)
    • 6.6.5 UAE
      • 6.6.5.1 Key Country Dynamics
      • 6.6.5.2 UAE Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (Revenue In USD Million And Volume In Thousand Units)
    • 6.6.6 Kuwait
      • 6.6.6.1 Key Country Dynamics
      • 6.6.6.2 Kuwait Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (Revenue In USD Million And Volume In Thousand Units)

Chapter 7 Competitive Analysis

  • 7.1 Company Categorization
    • 7.1.1 Fresenius Kabi AG
    • 7.1.2 Pfizer Inc.
    • 7.1.3 Otsuka Pharmaceutical Co. Ltd.
    • 7.1.4 Baxter, B. Braun Melsungen AG
    • 7.1.5 Vifor Pharma Management Ltd.
    • 7.1.6 JW Life Science
  • 7.2 Participants' Overview
  • 7.3 Financial Performance
  • 7.4 Product Benchmarking
  • 7.5 Market Participant Categorization
    • 7.5.1 Heat Map Analysis
  • 7.6 Company Market Share Analysis, 2022
  • 7.7 Strategy Mapping
    • 7.7.1 Mergers & Acquisitions
    • 7.7.2 Product Launch
    • 7.7.3 Partnerships & Collaborations
    • 7.7.4 Product Approvals
    • 7.7.5 Expansion
    • 7.7.6 Others

Chapter 8 Analyst Perspective

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦